Pelizzaro F, et al. - In this retrospective analysis, researchers assessed capecitabine activity and safety in a wide cohort of advanced hepatocellular carcinoma (HCC) patients. The study sample consisted of 143 capecitabine-treated patients (January 2010 to December 2017) in three centers of the Veneto Oncology Network. Data reported that median overall survival and time to progression were 6.9 and 2.8 months, respectively. In patients intolerant to sorafenib, capecitabine was more active than in patients progressing during treatment. Findings suggested that capecitabine in advanced HCC can be considered an active and safe option, particularly for patients who are not suitable for other treatments.